Skip to main content
Bicara Therapeutics Inc. logo

Bicara Therapeutics Inc. — Investor Relations & Filings

Ticker · BCAX ISIN · US0554771032 US Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2025-06-10 Director's Dealing
Country US United States of America
Listing US BCAX

About Bicara Therapeutics Inc.

https://www.bicara.com/

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class, dual-action biologics for cancer treatment. The company engineers bifunctional therapies that combine the precision of targeted treatments with the activation of a potent and durable anti-tumor immune response. This approach is designed to deliver therapeutic impact directly within the tumor microenvironment, with a primary focus on developing treatments for patients with solid tumors.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-06-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or agreements that are important to shareholders. The text specifically details the entry into a material definitive agreement (a Sublease Agreement) and references that the full agreement will be filed with the next Quarterly Report on Form 10-Q. There are no financial statements or comprehensive financial data presented here, only a description of the agreement and procedural information. The document length is under 5,000 characters and it serves as an announcement of a material event rather than a full financial report or earnings release. Therefore, it fits best into the Regulatory Filings (RNS) category, which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2025-06-06 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-15 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-13 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 - Results of Operations and Financial Condition, indicating a press release announcing quarterly financial results for the quarter ended March 31, 2025. The document states that the full text of the press release is furnished as an exhibit and incorporated by reference, but the 8-K itself is a brief filing announcing the earnings release. The document length is 3625 characters, which is relatively short and consistent with an earnings release announcement rather than a full financial report. According to the classification rules, initial announcements of quarterly financial results (key highlights only) correspond to the Earnings Release (ER) category. Therefore, this document should be classified as an Earnings Release (ER).
2025-05-13 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-12 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.